Serrated Polyposis Syndrome

Juárez, Míriam; Murcia, Óscar; Rodríguez–Soler, María; Jover, Rodrigo

doi:10.1007/978-3-319-28103-2_4

Cited by 1 publication

(1 citation statement)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both of these conditions could be potentially related to CIMP+ lesions. On one hand, CIMP+ lesions are traditionally related to flat or laterally spread right-sided polyps [ 12 , 13 , 14 ], with lesions that are commonly difficult to detect and resect—factors that are strongly linked to colonoscopy quality. On the other hand, CIMP+ lesions have been associated with fast oncogenic growth, especially when coexisting with other molecular alterations such as microsatellite instability [ 15 , 16 ].…”

Section: Discussionmentioning

confidence: 99%

Effects of Somatic Methylation in Colonic Polyps on Risk of Developing Metachronous Advanced Colorectal Lesions

Murcia

Martínez-Roca

Juárez

et al. 2021

Cancers

Self Cite

View full text Add to dashboard Cite

The utility of molecular markers for predicting the risk of metachronous advanced colorectal lesions (MACLs) remains poorly investigated. We examined the relationship between somatic hypermethylation in polyps at baseline and the risk of developing MACL. This retrospective cohort study included 281 consecutive patients with colonic polyps who were enrolled between 2007 and 2009 and followed-up until 2014. MACLs were defined as adenomas of ≥10 mm, high-grade dysplasia, or with a villous component; and serrated lesions of ≥10 mm or with dysplasia. In total, 595 polyps were removed at baseline colonoscopy and analyzed for pathological characteristics and CpG island methylator phenotype (CIMP) using the MS-MLPA (Methylation-Specific -- Multiplex Ligation-dependent Probe Amplification) technique. Forty-five patients (16.0%) showed at least one CIMP+ polyp. MACL risk was higher in patients with CIMP+ polyps (odds ratio (OR), 4.50; 95% CI, 1.78–11.4; p = 0.002). Patients with CIMP+ polyps also exhibited shorter time to MACL development (33.8 months vs. 50.1 months; p < 0.001), even with adjustment for polyp size and number (OR, 2.40; 95% CI, 1.33–4.34). Adding CIMP analysis improved the sensitivity (57.0% to 70.9%), negative predictive value (71.1% to 77.3%), and overall accuracy (49.8% to 52.0%) for MACL risk estimation. These results highlight that CIMP may be a useful marker for endoscopic surveillance.

show abstract